The Neuron Clinic, a leading neurology practice with six locations in Southern California and Positrigo, a Swiss based medical technology company developing nuclear medical imaging devices to advance functional brain imaging, announced the installation of the NeuroLF dedicated brain PET system at The Neuron Clinic’s San Marcos clinic, marking a major step forward in community-based neurological care. The NeuroLF system will serve as the cornerstone technology for The Neuron Clinic’s newly established Alzheimer’s & Dementia Care Center, designed to bring advanced diagnostic capabilities directly to patients and families seeking timely answers about cognitive decline.

The launch comes at a pivotal moment in neurodegenerative and Alzheimer’s care, as the adoption of blood-based biomarkers as an early triage tool, and the growth of advanced imaging biomarkers converge with the arrival of disease-modifying treatments. Blood tests are increasingly identifying patients who need confirmatory brain PET, which is critical to determining treatment eligibility, and monitoring therapeutic response. This shift is driving demand for a decentralized model that brings neurodiagnostic modalities directly into neurologic practices, shortening the time to diagnosis, personalizing treatment decisions, and keeping the full clinical pathway within the practice. 

The Neuron Clinic is the first independent neurology practice in the United States to own and operate a NeuroLF system. This breakthrough makes it possible to perform in-office, dedicated brain PET imaging - a critical tool for the early and accurate detection of Alzheimer's disease and related dementias – enabling early diagnosis and shortening the time to treatment without requiring patients to visit a hospital or external imaging facility.

The program also reflects a broader shift in reshaping access to advanced diagnostic care. Dr. Jose Soria, Medical Director of the program, emphasizes the importance of bringing brain PET directly into the community, noting that decentralizing neurodiagnostics allows neurologists to guide the entire diagnostic-to-treatment pathway with greater speed, coordination, and quality control. He highlights that this model “shortens the time to diagnosis, strengthens continuity of care, and ensures patients can receive evaluation, imaging, and treatment in a single, trusted environment—close to where they live.”

“Launching our Alzheimer’s & Dementia Center with NeuroLF at its core represents a transformation in how we can serve patients experiencing memory loss and cognitive symptoms,” states Dr. Branko Huisa, Founder and Medical Director of The Neuron Clinic. “Accurate diagnosis is the single most important step in providing effective care. With NeuroLF, we can identify Alzheimer’s disease earlier, with greater precision, and in an environment that is accessible and supportive for patients and their families.”

Positrigo’s NeuroLF system is specifically engineered for brain PET imaging, offering clinicians high-quality molecular imaging in an ultra-compact, cost-effective platform. Its ability to detect amyloid and other biomarkers associated with neurodegenerative disease makes it particularly suited for dementia evaluations.

“This collaboration embodies our mission to broaden access to advanced brain imaging,” says Dr. Jannis Fischer, Co-Founder and CEO of Positrigo. “By installing NeuroLF at the point of care, The Neuron Clinic is helping to ensure that patients with suspected Alzheimer’s or other dementias receive faster and more accurate diagnostic information. We are proud to support the launch of their Alzheimer’s & Dementia Care Center and are excited about the impact this will have on patient care and community health.”

The new Alzheimer’s & Dementia Care Center will integrate NeuroLF imaging with neurological evaluation, cognitive testing, and individualized treatment planning - creating a comprehensive, streamlined pathway for patients seeking clarity about cognitive decline. The clinic’s goal is to reduce diagnostic delays, expand access to biomarker-based assessment, and empower families with earlier interventions and informed decision-making.